P. Griffin

发表

Testicular tumors: delay in diagnosis and influence on survival.

G. Prout, P. Griffin, 1984, American family physician.

The treated histories of patients with Ta grade 1 transitional-cell carcinoma of the bladder.

G. Prout, P. Griffin, B. Bassil, 1986, Archives of surgery.

Invasive bladder cancer: tumor configuration, lymphatic invasion and survival.

W. Shipley, G. Prout, N. Heney, 1983, The Journal of urology.

Bladder carcinoma as a systemic disease

W. Shipley, G. Prout, P. Griffin, 1979, Cancer.

Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms

G. Prout, N. Heney, J. Daly, 1983, Cancer.

The outcome of conservative treatment of carcinoma in situ of the bladder.

G. Prout, J. Daly, P. Griffin, 1987, The Journal of urology.

Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis.

G. Prout, J. Daly, P. Griffin, 1976, Urology.

Radiochemotherapy for invasive carcinoma of the bladder.

W. Shipley, A. Althausen, G. Prout, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.

W. Shipley, C. Fung, R. Young, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total bone uptake in management of metastatic carcinoma of the prostate.

K. Mckusick, H. Strauss, G. Prout, 1987, The Journal of urology.

Long-term experience with flutamide in patients with prostatic carcinoma.

M. Keating, G. Prout, P. Griffin, 1989, Urology.

A refined method for assessing 99mTc-MDP whole body retention in prostate cancer patients.

K. Mckusick, H. Strauss, G. Prout, 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Altered androgen metabolism in metastatic prostate cancer.

G. Prout, J. Daly, P. Griffin, 1978, The Journal of urology.

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer

M. Borad, D. Northfelt, P. Lebowitz, 2010, Journal of clinical pharmacology.

Bladder preservation by combined modality therapy for invasive bladder cancer.

A. Zietman, W. Shipley, L. Kachnic, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective bladder preservation by combination treatment of invasive bladder cancer.

W. Shipley, A. Althausen, N. Heney, 1993, The New England journal of medicine.

Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin.

L. Marks, W. Shipley, G. Prout, 1988, International journal of radiation oncology, biology, physics.

Transitional cell carcinoma of renal pelvis.

G. Prout, N. Heney, J. Daly, 1982, Urology.

Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial.

W. Shipley, G. Prout, N. Heney, 1991, The Urologic clinics of North America.

Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

W. Shipley, A. Althausen, G. Prout, 1990, The Journal of urology.

Ta and T1 bladder cancer: location, recurrence and progression.

G. Prout, N. Heney, J. Daly, 1982, British journal of urology.

Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis.

G. Prout, J. Daly, P. Griffin, 1975, The Journal of urology.

Nodal involvement as a prognostic indicator in patients with prostatic carcinoma.

W. Shipley, G. Prout, J. Daly, 1980, The Journal of urology.

Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group.

G. Prout, P. Griffin, G. Friedell, 1992, The Journal of urology.

The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors.

W. Shipley, A. Althausen, G. Prout, 1990, Progress in clinical and biological research.

Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.

G. Prout, J. Daly, P. Griffin, 1982, The Journal of urology.

Radio-chemotherapy for invasive carcinoma of the bladder.

W. Shipley, A. Althausen, G. Prout, 1992, Frontiers of radiation therapy and oncology.

Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder.

U. Nseyo, J. Kinsey, G. Prout, 1987, The New England journal of medicine.

In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.

G. Prout, J. Daly, P. Griffin, 1976, The Journal of urology.

Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.

A. Zietman, W. Shipley, L. Kachnic, 1996, The cancer journal from Scientific American.

Photodynamic Therapy With Hematoporphyrin Derivative in the Treatment of Superficial Transitional-Cell Carcinoma of the Bladder

Chi-Wei Lin, James J. Daly, U. Nseyo, 1988 .

Nodal involvement as prognostic indicator in prostatic carcinoma.

W. Shipley, G. Prout, J. Daly, 1981, Urology.

Minocycline diffusion into benign prostatic hyperplasia.

T. Hensle, G. Prout, P. Griffin, 1977, The Journal of urology.

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer

M. Borad, D. Northfelt, P. Lebowitz, 2010, Journal of clinical pharmacology.